Browsing Tag
Nasdaq: RADX
2 posts
Radiopharm Theranostics (ASX: RAD) begins third cohort in PD-L1 trial—could 177Lu-RAD204 be a game-changer?
Radiopharm Theranostics moves to third cohort in PD-L1 trial with 90mCi dose approval. Explore what this means for its radiopharmaceutical ambitions.
Radiopharm Theranostics (ASX: RAD) crashes 21.6% despite A$40m capital raise and clinical milestones
Radiopharm Theranostics shares fall 21.6% after A$40m raise, but strong clinical updates and Lantheus support point to long-term upside. Read the full investor breakdown.